Development of COVID-2019 main protease inhibitors as potential antivirals against the 2019 coronavirus.
Development of COVID-2019 main protease inhibitors as potential antivirals against the 2019 coronavirus.
开发 COVID-2019 主要蛋白酶抑制剂作为针对 2019 年冠状病毒的潜在抗病毒药物。
批准号：
422713
负责人：
Moitessier Nicolas R
金额：
$14.79万
依托单位：
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-02-01 至 2021-08-01
中文摘要
翻译
冠状病毒与多种人类疾病有关，从普通感冒到新的严重疾病，如2002年出现的严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)
英文摘要
Coronaviruses are associated with a variety of human diseases ranging from the common cold to new and serious conditions such as Severe Acute Respiratory Syndrome (SARS), which emerged in 2002, Middle Eastern Respiratory Syndrome (MERS), first reported in
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
COVID-19 Variant Supplement - Development of COVID-2019 main protease inhibitors as potential antivirals against the 2019 coronavirus.
-
批准号：443278
-
项目类别：Operating Grants
-
资助金额：$3.64万
-
财政年份：2021
-
负责人：Moitessier Nicolas R
-
依托单位：
From Rational Design To in vivo Evaluation of Dual Covalent Prolyl Oligopeptidase / Fibroblast Activation Protein Inhibitors as Potential Cancer Therapeutics.
-
批准号：304789
-
项目类别：Operating Grants
-
资助金额：$27.05万
-
财政年份：2014
-
负责人：Moitessier Nicolas R
-
依托单位：
海外基金
